<DOC>
	<DOC>NCT00146614</DOC>
	<brief_summary>The purpose of this study is to determine if the incidence of Graft vs. Host Disease (GVHD) after non-myeloablative transplantation can be reduced by using a combination of three immune suppressive medication; sirolimus, tacrolimus and methotrexate.</brief_summary>
	<brief_title>Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation</brief_title>
	<detailed_description>- Patients will be admitted to the hospital and receive chemotherapy and stem cell transplant(SCT). The total duration of hospitalization for the procedure is approximately 8 days. Once admitted the patient will receive fludarabine daily for 4 days, busulfex once daily for 4 days. Two days after chemotherapy has ended, the patient will receive the infusion of donor cells. - Just prior to the transplant and following the transplant, patients will receive sirolimus (orally), tacrolimus (orally) and low doses of methotrexate (chemotherapy). Methotrexate will be given on days 1,3 and 6 after transplant. - Sirolimus will be tapered beginning week 9 after transplant if there is no evidence of GVHD and will be eliminated on week 26 if clinically feasible. - Tacrolimus will be tapered beginning week 9 after transplant if there is no evidence of GVHD and will be eliminated on week 26 if clinically feasible. - Patients will also receive medication to help prevent possible infection. - After stem cell infusion, patients will be examined and have blood tests weekly for 1 month. At the 1 month visit, a bone marrow biopsy will performed looking for evidence of donor cells in the bone marrow. After the one month evaluation the patient will be examined every 2 weeks and a repeat bone marrow performed 3-4 months after transplant.</detailed_description>
	<mesh_term>Graft vs Host Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients with hematologic malignancies who are at a high risk of complications after conventional transplantation. Donors (both related and unrelated) who are identical at 6 HLA loci. Age greater than 18 ECOG Performance Status 02 Life expectancy of greater than 100 days. Pregnancy Evidence of HIV infection Heart failure uncontrolled by medications Total Bilirubin &gt; 2.0mg/dl due to hepatocellular dysfunction AST &gt; 90 Serum creatinine &gt; 2.0 Cholesterol &gt; 300 mg/dl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Graft versus Host Disease</keyword>
	<keyword>GVHD</keyword>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>allogeneic stem cell transplantation</keyword>
</DOC>